CHRISTIAN HANSEN |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
+2.93% | -1.82% |
| 02-02 | Novozymes, Chr. Hansen Complete Merger Settlement | MT |
| 02-02 | Chr. Hansen Holding A/S(CPSE:CHR) dropped from OMX Nordic All-Share Index | CI |
Business Summary
- cultivations and enzymes (62.6%);
- medical and nutritional ingredients (37.4%): used in the manufacturing of dietary supplements, OTC drugs, baby products and animal feed.
Net sales are distributed geographically as follows: Denmark (0.8%), Europe/Middle East/Africa (36.4%), the United States (30.3%), North America (2.4%), Asia/Pacific (18.7%) and Latin America (11.4%).
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 131,852,496 | 95,790,519 ( 72.65 %) | 250,269 ( 0.1898 %) | 72.65 % |
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
Chr. Hansen A/S
 Chr. Hansen A/S Pharmaceuticals: OtherHealth Technology Chr. Hansen A/S engages in bioscience research that develops natural solutions for the food, nutritional, pharmaceutical and agricultural industries. It also develops and produces cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed. The company was founded by Christian D. A Hansen in 1874 and is headquartered in Horsholm, Denmark. |
Pharmaceuticals: Other
|
Trading Rating
Investor Rating
ESG Refinitiv
| 1st Jan change | Capi. | |
|---|---|---|
| +0.13% | 29.22B | |
| +23.12% | 25.46B | |
| +4.67% | 11.06B | |
| +18.43% | 4.47B | |
| -8.30% | 3.83B | |
| +2.12% | 3.4B | |
| +0.07% | 2.99B | |
| +25.54% | 2.79B | |
| -9.05% | 2.49B |
- Stock Market
- Equities
- CHR Stock
- 51C Stock
- Company Christian Hansen
